2.2.0.25truefalse41001 - Disclosure - Collaborative Arrangements (Details)truefalsefalse1falsefalseUSDfalsefalse1/1/2010 - 12/31/2010
USD ($)
USD ($) / shares
$Duration_1_1_2010_To_12_31_2010http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0USDUSD$2falsefalseUSDfalsefalse1/1/2009 - 12/31/2009
USD ($)
USD ($) / shares
$Duration_1_1_2009_To_12_31_2009http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0USDUSD$3falsefalseUSDfalsefalse1/1/2008 - 12/31/2008
USD ($)
USD ($) / shares
$Duration_1_1_2008_To_12_31_2008http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit1Standardhttp://www.xbrl.org/2003/instancesharesxbrli0Unit14Dividehttp://www.xbrl.org/2003/iso4217USDiso4217http://www.xbrl.org/2003/instancesharesxbrli0Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$4falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Renexa Product [Member]
{dei_LegalEntityAxis} : Roche [Member]
7/1/2008 - 7/31/2008
USD ($)
$Duration_7_1_2008_To_7_31_2008http://www.sec.gov/CIK0000882095duration2008-07-01T00:00:002008-07-31T00:00:00falsefalseRenexa Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_RenexaProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseRoche [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_RocheMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Renexa Product [Member]
{dei_LegalEntityAxis} : Roche [Member]
1/1/2006 - 1/31/2006
USD ($)
$Duration_1_1_2006_To_1_31_2006http://www.sec.gov/CIK0000882095duration2006-01-01T00:00:002006-01-31T00:00:00falsefalseRenexa Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_RenexaProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseRoche [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_RocheMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hespera Product [Member]
{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2009 - 3/31/2009
USD ($)
$Duration_1_1_2009_To_3_31_2009http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-03-31T00:00:00falsefalseHespera Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_HesperaProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$7falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hespera Product [Member]
{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20086http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseHespera Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_HesperaProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Hespera Product [Member]
{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2007 - 12/31/2007
USD ($)
$Duration_1_1_2007_To_12_31_200722http://www.sec.gov/CIK0000882095duration2007-01-01T00:00:002007-12-31T00:00:00falsefalseHespera Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_HesperaProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$9falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Volibris Product [Member]
{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010227http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseVolibris Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_VolibrisProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Volibris Product [Member]
{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_2009215http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseVolibris Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_VolibrisProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$11falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Volibris Product [Member]
{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20087http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseVolibris Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_VolibrisProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$12falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Lexiscan Product [Member]
{dei_LegalEntityAxis} : Astellas US LLC and Astellas Pharma US, Inc. [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201023226http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseLexiscan Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_LexiscanProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseAstellas US LLC and Astellas Pharma US, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_AstellasUsLlcAndAstellasPharmaUsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$13falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : Lexiscan Product [Member]
{dei_LegalEntityAxis} : Astellas US LLC and Astellas Pharma US, Inc. [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_200922215http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseLexiscan Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_LexiscanProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseAstellas US LLC and Astellas Pharma US, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_AstellasUsLlcAndAstellasPharmaUsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$14falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : TCM278 Product [Member]
{dei_LegalEntityAxis} : Tibotec Pharmaceuticals [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201023210http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseTCM278 Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TcmTwoSevenEightProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseTibotec Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_TibotecPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$15falsefalseEURtruefalse{us-gaap_ProductOrServiceAxis} : TCM278 Product [Member]
{dei_LegalEntityAxis} : Tibotec Pharmaceuticals [Member]
1/1/2010 - 12/31/2010
EUR (€)
€Duration_1_1_2010_To_12_31_201023210http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseTCM278 Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TcmTwoSevenEightProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseTibotec Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_TibotecPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit15Standardhttp://www.xbrl.org/2003/iso4217EURiso42170EUREUR€16falsefalseUSDtruefalse{us-gaap_ProductOrServiceAxis} : TCM278 Product [Member]
{dei_LegalEntityAxis} : Tibotec Pharmaceuticals [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_200933http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseTCM278 Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TcmTwoSevenEightProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseTibotec Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_TibotecPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$17falsefalseEURtruefalse{us-gaap_ProductOrServiceAxis} : TCM278 Product [Member]
{dei_LegalEntityAxis} : Tibotec Pharmaceuticals [Member]
1/1/2009 - 12/31/2009
EUR (€)
€Duration_1_1_2009_To_12_31_200933http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseTCM278 Product [Member]us-gaap_ProductOrServiceAxisxbrldihttp://xbrl.org/2006/xbrldigild_TcmTwoSevenEightProductMemberus-gaap_ProductOrServiceAxisexplicitMemberfalsefalseTibotec Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_TibotecPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit15Standardhttp://www.xbrl.org/2003/iso4217EURiso42170EUREUR€18falsefalsetruefalse{us-gaap_DeferredRevenueArrangementTypeAxis} : Tamiflu Royalty Arrangement [Member]
{dei_LegalEntityAxis} : Roche [Member]
1/1/2009 - 12/31/2009
Duration_1_1_2009_To_12_31_2009222http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseTamiflu Royalty Arrangement [Member]us-gaap_DeferredRevenueArrangementTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_RoyaltyArrangementMemberus-gaap_DeferredRevenueArrangementTypeAxisexplicitMemberfalsefalseRoche [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_RocheMemberdei_LegalEntityAxisexplicitMember19falsefalseUSDtruefalse{us-gaap_DeferredRevenueArrangementTypeAxis} : Up-front Payments [Member]
{dei_LegalEntityAxis} : Parion Sciences, Inc. [Member]
8/1/2007 - 8/31/2007
USD ($)
$Duration_8_1_2007_To_8_31_2007http://www.sec.gov/CIK0000882095duration2007-08-01T00:00:002007-08-31T00:00:00falsefalseUp-front Payments [Member]us-gaap_DeferredRevenueArrangementTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_UpFrontPaymentArrangementMemberus-gaap_DeferredRevenueArrangementTypeAxisexplicitMemberfalsefalseParion Sciences, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_ParionSciencesIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$20falsefalseUSDtruefalse{us-gaap_DeferredRevenueArrangementTypeAxis} : Up-front Payments [Member]
{dei_LegalEntityAxis} : Japan Tobacco Inc. [Member]
3/1/2005 - 3/31/2005
USD ($)
$Duration_3_1_2005_To_3_31_2005http://www.sec.gov/CIK0000882095duration2005-03-01T00:00:002005-03-31T00:00:00falsefalseUp-front Payments [Member]us-gaap_DeferredRevenueArrangementTypeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_UpFrontPaymentArrangementMemberus-gaap_DeferredRevenueArrangementTypeAxisexplicitMemberfalsefalseJapan Tobacco Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_JapanTobaccoIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$21falsefalseUSDtruefalse{dei_LegalEntityAxis} : PARI GmbH [Member]
11/1/2007 - 11/30/2007
USD ($)
$Duration_11_1_2007_To_11_30_2007http://www.sec.gov/CIK0000882095duration2007-11-01T00:00:002007-11-30T00:00:00falsefalsePARI GmbH [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_PariGmbhMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$22falsefalseUSDtruefalse{dei_LegalEntityAxis} : Parion Sciences, Inc. [Member]
8/31/2007
USD ($)
$As_Of_8_31_2007http://www.sec.gov/CIK0000882095instant2007-08-31T00:00:000001-01-01T00:00:00falsefalseParion Sciences, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_ParionSciencesIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$23falsefalseUSDtruefalse{dei_LegalEntityAxis} : Japan Tobacco Inc. [Member]
7/1/2008 - 7/31/2008
USD ($)
$Duration_7_1_2008_To_7_31_20082http://www.sec.gov/CIK0000882095duration2008-07-01T00:00:002008-07-31T00:00:00falsefalseJapan Tobacco Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_JapanTobaccoIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$24falsefalseUSDtruefalse{dei_LegalEntityAxis} : Japan Tobacco Inc. [Member]
3/1/2006 - 3/31/2006
USD ($)
$Duration_3_1_2006_To_3_31_20062http://www.sec.gov/CIK0000882095duration2006-03-01T00:00:002006-03-31T00:00:00falsefalseJapan Tobacco Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_JapanTobaccoIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$25falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
3/1/2006 - 3/31/2006
USD ($)
$Duration_3_1_2006_To_3_31_2006http://www.sec.gov/CIK0000882095duration2006-03-01T00:00:002006-03-31T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$26falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
4/1/2002 - 4/30/2002
USD ($)
$Duration_4_1_2002_To_4_30_2002http://www.sec.gov/CIK0000882095duration2002-04-01T00:00:002002-04-30T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$27falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201023http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0Unit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$28falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_200922213http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$29falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_20082http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$30falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2007 - 12/31/2007
USD ($)
$Duration_1_1_2007_To_12_31_2007http://www.sec.gov/CIK0000882095duration2007-01-01T00:00:002007-12-31T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$31falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2006 - 12/31/2006
USD ($)
$Duration_1_1_2006_To_12_31_2006http://www.sec.gov/CIK0000882095duration2006-01-01T00:00:002006-12-31T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$32falsefalseUSDtruefalse{dei_LegalEntityAxis} : GlaxoSmithKline Inc. [Member]
1/1/2004 - 12/31/2004
USD ($)
$Duration_1_1_2004_To_12_31_2004http://www.sec.gov/CIK0000882095duration2004-01-01T00:00:002004-12-31T00:00:00falsefalseGlaxoSmithKline Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_GlaxosmithklineIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$33falsefalseUSDtruefalse{dei_LegalEntityAxis} : Roche [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_2010230http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseRoche [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_RocheMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170Unit13Standardhttp://www.xbrl.org/2003/instancepurexbrli0USDUSD$34falsefalseUSDtruefalse{dei_LegalEntityAxis} : Roche [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_200922214http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseRoche [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_RocheMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$35falsefalseUSDtruefalse{dei_LegalEntityAxis} : Roche [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_200816http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseRoche [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_RocheMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$36falsefalseUSDtruefalse{dei_LegalEntityAxis} : Astellas US LLC and Astellas Pharma US, Inc. [Member]
1/1/2010 - 12/31/2010
USD ($)
$Duration_1_1_2010_To_12_31_201023225http://www.sec.gov/CIK0000882095duration2010-01-01T00:00:002010-12-31T00:00:00falsefalseAstellas US LLC and Astellas Pharma US, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_AstellasUsLlcAndAstellasPharmaUsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$37falsefalseUSDtruefalse{dei_LegalEntityAxis} : Astellas US LLC and Astellas Pharma US, Inc. [Member]
1/1/2009 - 12/31/2009
USD ($)
$Duration_1_1_2009_To_12_31_200922212http://www.sec.gov/CIK0000882095duration2009-01-01T00:00:002009-12-31T00:00:00falsefalseAstellas US LLC and Astellas Pharma US, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_AstellasUsLlcAndAstellasPharmaUsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$38falsefalseUSDtruefalse{dei_LegalEntityAxis} : Astellas US LLC and Astellas Pharma US, Inc. [Member]
1/1/2008 - 12/31/2008
USD ($)
$Duration_1_1_2008_To_12_31_200815http://www.sec.gov/CIK0000882095duration2008-01-01T00:00:002008-12-31T00:00:00falsefalseAstellas US LLC and Astellas Pharma US, Inc. [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_AstellasUsLlcAndAstellasPharmaUsIncMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$39falsefalseEURtruefalse{dei_LegalEntityAxis} : Tibotec Pharmaceuticals [Member]
7/1/2009 - 7/31/2009
EUR (€)
€Duration_7_1_2009_To_7_31_2009http://www.sec.gov/CIK0000882095duration2009-07-01T00:00:002009-07-31T00:00:00falsefalseTibotec Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_TibotecPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit15Standardhttp://www.xbrl.org/2003/iso4217EURiso42170EUREUR€40falsefalseUSDtruefalse{dei_LegalEntityAxis} : Tibotec Pharmaceuticals [Member]
7/1/2009 - 7/31/2009
USD ($)
$Duration_7_1_2009_To_7_31_2009http://www.sec.gov/CIK0000882095duration2009-07-01T00:00:002009-07-31T00:00:00falsefalseTibotec Pharmaceuticals [Member]dei_LegalEntityAxisxbrldihttp://xbrl.org/2006/xbrldigild_TibotecPharmaceuticalsMemberdei_LegalEntityAxisexplicitMemberUnit12Standardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false0us-gaap_VariableInterestEntityCarryingAmountOfCollateralizedAssetsus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse14500000001450000000falsetruefalsefalsefalse2truefalsefalse14000000001400000000falsetruefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe carrying amount of the variable interest entity's assets consolidated into the statement of financial position. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 26
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4 and FIN46(R)-8
-Paragraph 9
-Subparagraph c(5), c(6)
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 23
-Subparagraph a
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4 and FIN46(R)-8
-Paragraph C5
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 23
-Subparagraph b
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 24
-Subparagraph b
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4 and FIN46(R)-8
-Paragraph C8
-Subparagraph b
falsefalse6false0us-gaap_VariableInterestEntityCarryingAmountOfLiabilitiesConsolidatedVIEus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1truefalsefalse759500000759500000falsefalsefalsefalsefalse2truefalsefalse10300000001030000000falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe carrying amount of the variable interest entity's liabilities consolidated into the statement of financial position. In general, a VIE is a corporation, partnership, trust, or any other legal structure used for business purposes that either (a) does not have equity investors with voting rights or (b) has equity investors that do not provide sufficient financial resources for the entity to support its activities. A VIE often holds financial assets, including loans or receivables, real estate or other property. A VIE may be essentially passive or it may engage in research and development or other activities on behalf of another company.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4 and FIN46(R)-8
-Paragraph C8
-Subparagraph b
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 23
-Subparagraph b
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 24
-Subparagraph b
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 23
-Subparagraph a
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4 and FIN46(R)-8
-Paragraph C6
-Subparagraph a
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4 and FIN46(R)-8
-Paragraph 9
-Subparagraph c(5), c(6)
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 46R
-Paragraph 26
-Subparagraph b
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS140-4 and FIN46(R)-8
-Paragraph C5
-Subparagraph a
falsefalse7false0gild_AmountPaidToReduceRoyaltyRategildfalsedebitdurationAmount Paid To Reduce The Royalty Ratefalsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21truefalsefalse1350000013500000falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount Paid To Reduce The Royalty RateNo authoritative reference available.falsefalse8false0us-gaap_CostMethodInvestmentsAggregateCarryingAmountus-gaaptruedebitinstantNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22truefalsefalse50000005000000falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThis element represents the aggregate carrying amount of all cost-method investments held by the Company. Generally, such investments do not have readily determinable fair values and are not required to be accounted for by the equity method. The carrying amount of such securities equates to cost, adjusted for other-than-temporary impairment. The cost method and lower-of-cost or market, an adaptation of the cost method, is generally followed for most investments in noncontrolled corporations, in some corporate joint ventures, and to a lesser extent in unconsolidated subsidiaries, particularly foreign.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 22
-Subparagraph a
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 18
-Subparagraph a
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 5
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 4
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 4
-Subparagraph c
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 18
-Paragraph 6
-Subparagraph a
falsefalse9false0gild_RoyaltyArrangementTermsgildfalsenadurationTerms of Royalty Arrangement including: percentage of net sales paid as royalties and sales level tiers for determining...falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00<font class="_mt"><font style="font-family: Times New Roman;" class="_mt" size="2">The royalties payable to us on net sales of Tamiflu sold by Roche remain the same under the amended agreement, which are as follows: (a) 14% of the first $200.0 million in worldwide net sales in a given calendar year; (b) 18% of the next $200.0 million in worldwide net sales during the same calendar year; and (c) 22% of worldwide net sales in excess of $400.0 million during the same calendar year.</font></font>The royalties payable to us on net sales of Tamiflu sold by Roche remain the same under the amended agreement, which are as follows: (a) 14% of the firstfalsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:stringItemTypestringTerms of Royalty Arrangement including: percentage of net sales paid as royalties and sales level tiers for determining appropriate percentage.No authoritative reference available.falsefalse10false0gild_PaymentInAccordanceWithAgreementgildfalsedebitdurationPayment in accordance with agreementfalsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4truefalsefalse90000009000000falsefalsefalsetruefalse5truefalsefalse1100000011000000falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryPayment in accordance with agreementNo authoritative reference available.falsefalse11false0us-gaap_FiniteLivedIntangibleAssetsUsefulLifeus-gaaptruenadurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33truefalsefalse1111falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerThe useful life of all finite-lived intangible assets. This may be stated as a fixed number (for example, 10 years) if all assets have the same useful life, or it can be stated in a range (for example, six to eight years) if there is a range of useful lives in the asset group.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 142
-Paragraph 12, 13, 14
falsefalse12false0us-gaap_ResearchAndDevelopmentExpenseus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14truefalsefalse2210000022100000falsefalsefalsetruefalse15truefalsefalse1790000017900000falsefalsefalsetruefalse16truefalsefalse5240000052400000falsefalsefalsetruefalse17truefalsefalse3570000035700000falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19truefalsefalse50000005000000falsefalsefalsetruefalse20truefalsefalse1500000015000000falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23truefalsefalse70000007000000falsefalsefalsetruefalse24truefalsefalse50000005000000falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryThe aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 141
-Paragraph 51
-Subparagraph g
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 2
-Paragraph 12, 13
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 86
-Paragraph 11, 12
falsefalse13false0gild_MilestonePaymentsReceivedgildfalsecreditdurationmilestone Payments Receivedfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29truefalsefalse2000000020000000falsefalsefalsetruefalse30truefalsefalse1100000011000000falsefalsefalsetruefalse31truefalsefalse1000000010000000falsefalsefalsetruefalse32truefalsefalse1700000017000000falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetarymilestone Payments ReceivedNo authoritative reference available.falsefalse14false0gild_FutureMilestoneReceivablesgildfalsedebitdurationFuture milestone receivablesfalsefalsefalsefalsefalsefalsefalsefalsefalsefalselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27truefalsefalse8000000080000000falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryFuture milestone receivablesNo authoritative reference available.falsefalse15false0us-gaap_DeferredRevenueRevenueRecognizedus-gaaptruedebitdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalse1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6truefalsefalse2450000024500000falsefalsefalsetruefalse7truefalsefalse34000003400000falsefalsefalsetruefalse8truefalsefalse36000003600000falsefalsefalsetruefalse9truefalsefalse87000008700000falsefalsefalsetruefalse10truefalsefalse83000008300000falsefalsefalsetruefalse11truefalsefalse50000005000000falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryAmount of previously reported deferred or unearned revenue that was recognized as revenue during the period. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 13
-Section A
falsefalse16false0gild_GrossSalesLimitForAchievementgildfalsecreditdurationGross Sales limit For Achievementfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31truefalsefalse7500000075000000falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryGross Sales limit For AchievementNo authoritative reference available.falsefalse17false0gild_UpFrontPaymentReceivedgildfalsecreditdurationUp-front payment receivedfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25truefalsefalse2000000020000000falsefalsefalsetruefalse26truefalsefalse1000000010000000falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryUp-front payment receivedNo authoritative reference available.falsefalse18false0gild_NoOfYearMilestoneAndUpFrontLicensePaymentsAmortizedgildfalsenadurationNo Of Year Milestone And Up Front License Payments Amortizedfalsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27truefalsefalse66falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseOtherxbrli:integerItemTypeintegerNo Of Year Milestone And Up Front License Payments AmortizedNo authoritative reference available.falsefalse19false0us-gaap_RoyaltyRevenueus-gaaptruecreditdurationNo definition available.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseverboselabel1truefalsefalse545970000545970000falsefalsefalsefalsefalse2truefalsefalse491818000491818000falsefalsefalsefalsefalse3truefalsefalse218180000218180000falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12truefalsefalse4320000043200000falsefalsefalsetruefalse13truefalsefalse1970000019700000falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27truefalsefalse4800000048000000falsefalsefalsetruefalse28truefalsefalse3240000032400000falsefalsefalsetruefalse29truefalsefalse3170000031700000falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33truefalsefalse386500000386500000falsefalsefalsetruefalse34truefalsefalse392700000392700000falsefalsefalsetruefalse35truefalsefalse155500000155500000falsefalsefalsetruefalse36truefalsefalse1020000010200000falsefalsefalsetruefalse37truefalsefalse94000009400000falsefalsefalsetruefalse38truefalsefalse95000009500000falsefalsefalsetruefalse39falsefalsefalse00falsefalsefalsetruefalse40falsefalsefalse00falsefalsefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryRevenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 1
-Article 5
falsefalse20false0gild_ResearchAndDevelopmentReimbursementContractMaximumgildfalsecreditdurationResearch and development reimbursement contract maximum.falsefalsefalsefalsefalsefalsefalsefalsefalsefalseterselabel1falsefalsefalse00falsefalsefalsefalsefalse2falsefalsefalse00falsefalsefalsefalsefalse3falsefalsefalse00falsefalsefalsefalsefalse4falsefalsefalse00falsefalsefalsetruefalse5falsefalsefalse00falsefalsefalsetruefalse6falsefalsefalse00falsefalsefalsetruefalse7falsefalsefalse00falsefalsefalsetruefalse8falsefalsefalse00falsefalsefalsetruefalse9falsefalsefalse00falsefalsefalsetruefalse10falsefalsefalse00falsefalsefalsetruefalse11falsefalsefalse00falsefalsefalsetruefalse12falsefalsefalse00falsefalsefalsetruefalse13falsefalsefalse00falsefalsefalsetruefalse14falsefalsefalse00falsefalsefalsetruefalse15falsefalsefalse00falsefalsefalsetruefalse16falsefalsefalse00falsefalsefalsetruefalse17falsefalsefalse00falsefalsefalsetruefalse18falsefalsefalse00falsefalsefalsetruefalse19falsefalsefalse00falsefalsefalsetruefalse20falsefalsefalse00falsefalsefalsetruefalse21falsefalsefalse00falsefalsefalsetruefalse22falsefalsefalse00falsefalsefalsetruefalse23falsefalsefalse00falsefalsefalsetruefalse24falsefalsefalse00falsefalsefalsetruefalse25falsefalsefalse00falsefalsefalsetruefalse26falsefalsefalse00falsefalsefalsetruefalse27falsefalsefalse00falsefalsefalsetruefalse28falsefalsefalse00falsefalsefalsetruefalse29falsefalsefalse00falsefalsefalsetruefalse30falsefalsefalse00falsefalsefalsetruefalse31falsefalsefalse00falsefalsefalsetruefalse32falsefalsefalse00falsefalsefalsetruefalse33falsefalsefalse00falsefalsefalsetruefalse34falsefalsefalse00falsefalsefalsetruefalse35falsefalsefalse00falsefalsefalsetruefalse36falsefalsefalse00falsefalsefalsetruefalse37falsefalsefalse00falsefalsefalsetruefalse38falsefalsefalse00falsefalsefalsetruefalse39truefalsefalse7150000071500000falsetruefalsetruefalse40truefalsefalse100000000100000000falsetruefalsetruefalseMonetaryxbrli:monetaryItemTypemonetaryResearch and development reimbursement contract maximum.No authoritative reference available.falsefalse4016Collaborative Arrangements (Details)NoRoundingUnKnownUnKnownUnKnowntruetrue
